# SIGA earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/SIGA) · [Earnings tab](https://www.lopjlb.com/stock/SIGA?tab=earnings)

Updated: 2026-11-09T04:41:42

Quarters analyzed: 8

## Cross-quarter narrative

Across the six earnings calls, SIGA’s financial footing stayed robust with cash above $100 million and a recurring $0.60 special dividend, while operating profitability slipped from modest pre‑tax income in late‑2024 to operating losses in 2025‑2026. Order visibility surged in Q3 2024 with $146 million of outstanding orders and new international demand, but later quarters described lumpy government procurement and slower US contract progress, creating demand volatility. The company advanced several regulatory and commercial milestones: a Vanderbilt monoclonal‑antibody license was secured, the PEP indication for TPOXX moved toward a 2026 submission, and Japan NDA work continued, while mpox‑trial results were delivered. IV TPOXX technology transfer progressed from a delay to an exercised option and ongoing transfer. International expansion accelerated via a Hikma MENA distribution deal and a $13 million Asia‑Pacific order. However, new long‑term US SNS contract negotiations showed repeated timing uncertainty, and European regulators signaled a potential label withdrawal for MPOXX, adding regulatory risk. Overall, SIGA’s capital strength and dividend policy remain stable, but margin pressure, contract delays, and regulatory headwinds temper the upbeat demand narrative.

## Latest CallCard · Q2

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q2:** —
- **2026 Q1:** SIGA reports minimal Q1 deliveries, expects $13M oral TPOXX delivery in Q2, announces Hikma MENA distribution deal, advances pediatric and PEP programs, pays $0.60 special dividend with $146M cash. No formal full-year guidance.
- **2025 Q3:** SIGA reports $86M 9-month product revenue, $172M cash, no debt; expects 2026 international sales; EMA review pending; PEP submission targeted 2026; government shutdown may delay CDC analysis.','tone': {'mgmt': 0.5, 'mgmt_rationale': 'Management highlights progress across key initiatives, strong fina
- **2025 Q2:** —
- **2025 Q1:** SIGA Q1 2025: $6M international sales, $62M US deliveries in April, $26M IV option exercised, $14M manufacturing funding added, PEP submission targeting H1 2026, $0.60 special dividend, $162M cash, no debt. Momentum continuing with broadened international scope and government support. Pipeline advan
- **2024 Q4:** SIGA reports 2024 product sales of $133M (+2% YoY), $155M cash, no debt, $70M outstanding orders for 2025 delivery; advancing TPOXX PEP submission targeting early 2026, Japan approval, international expansion, and seeking new SNS contract in 2025.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management
- **2024 Q3:** SIGA reports $122M Q3 orders, $146M outstanding, targeting new 5-10yr SNS contract in 2025; licenses mAb portfolio from Vanderbilt; PEP submission planned Q3 2025; mpox resistance <1%.
- **2024 Q2:** SIGA reports strong Q2

## Theme arcs

- **Demand visibility and order flow** (improving): Strong Q3 2024 order book grew, later described as lumpy but still expanding internationally
- **Financial strength and dividend policy** (stable): Cash consistently >$100 M, no debt, $0.60 special dividend each quarter
- **Operating margins** (deteriorating): From modest pre‑tax profit in late‑2024 to operating losses in 2025‑2026
- **Regulatory progress (PEP, Japan NDA)** (improving): PEP submission targeting 2026, Japan NDA work ongoing
- **US government contract acquisition** (deteriorating): New SNS contract timing repeatedly uncertain, progress slower than prior cycles
- **International expansion** (improving): Hikma MENA deal, Asia‑Pacific order, repeat international sales
- **Pipeline execution (pediatric, mpox trials)** (stable): Milestones on track, but dependent on clinical and regulatory outcomes

## Fear persistence

- **mpox resistance (<1%)** [resolved]: Low resistance reported once, no further mention
- **Regulatory: CHMP withdrawal recommendation for MPOXX** [new]: European regulator suggested label withdrawal, raising risk

## Guidance path

2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2026 Q1:vague → 2026 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/SIGA`